Seeking Alpha
26 Aug 2026, 12:54 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
The FDA agreed that uniQure's three-year AMT-130 data set for Huntington's disease can serve as the primary basis for a BLA under accelerated approval. — FDA alignment on an accelerated approval pathway significantly reduces time-to-market and derisks the clinical timeline for a gene therapy.
+0.80Boston Scientific faces slower uptake of its Watchman device and faster-than-expected market share loss in electrophysiology. — Loss of market share and slowing adoption of a key product directly impair revenue growth and competitive positioning.
-0.60Boston Scientific has reduced its growth outlook. — Lowered guidance typically leads to downward valuation adjustments and reduced investor confidence in near-term performance.
-0.50Which stocks this story touches
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
5h ago
